ATE485268T1 - Pyrrolidin-derivate als erk-hemmer - Google Patents
Pyrrolidin-derivate als erk-hemmerInfo
- Publication number
- ATE485268T1 ATE485268T1 AT07750497T AT07750497T ATE485268T1 AT E485268 T1 ATE485268 T1 AT E485268T1 AT 07750497 T AT07750497 T AT 07750497T AT 07750497 T AT07750497 T AT 07750497T AT E485268 T1 ATE485268 T1 AT E485268T1
- Authority
- AT
- Austria
- Prior art keywords
- pyrrolidine derivatives
- erk inhibitors
- erk
- inhibitors
- pyrrolidine
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US77404306P | 2006-02-16 | 2006-02-16 | |
PCT/US2007/003665 WO2007097937A1 (en) | 2006-02-16 | 2007-02-13 | Pyrrolidine derivatives as erk inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
ATE485268T1 true ATE485268T1 (de) | 2010-11-15 |
Family
ID=38170991
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AT07750497T ATE485268T1 (de) | 2006-02-16 | 2007-02-13 | Pyrrolidin-derivate als erk-hemmer |
Country Status (17)
Country | Link |
---|---|
US (1) | US7807672B2 (de) |
EP (1) | EP1984331B1 (de) |
JP (1) | JP2009528280A (de) |
KR (1) | KR20080103996A (de) |
CN (1) | CN101415674A (de) |
AR (1) | AR059493A1 (de) |
AT (1) | ATE485268T1 (de) |
AU (1) | AU2007218059A1 (de) |
CA (1) | CA2642762A1 (de) |
DE (1) | DE602007009932D1 (de) |
ES (1) | ES2353437T3 (de) |
HK (1) | HK1117159A1 (de) |
IL (1) | IL193413A0 (de) |
MX (1) | MX2008010635A (de) |
TW (1) | TW200745089A (de) |
WO (1) | WO2007097937A1 (de) |
ZA (1) | ZA200807457B (de) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
CA2706453A1 (en) * | 2007-11-30 | 2009-06-11 | Schering Corporation | Braf biomarkers |
NZ587504A (en) * | 2008-02-21 | 2012-09-28 | Merck Sharp & Dohme | Benzopyrazole derivatives as ERK inhibitors |
DE102008022221A1 (de) | 2008-05-06 | 2009-11-12 | Universität des Saarlandes | Inhibitoren der humanen Aldosteronsynthase CYP11B2 |
US9229008B2 (en) | 2008-08-19 | 2016-01-05 | Merck Sharp & Dohme Corp. | IL-8 level as a determinant of responsivity of a cancer to treatment |
CA2757368C (en) * | 2009-04-02 | 2019-03-12 | Merck Patent Gmbh | Piperidine and piperazine derivatives as autotaxin inhibitors |
EP2448942B1 (de) | 2009-07-02 | 2014-09-24 | Merck Sharp & Dohme Corp. | KONDENSIERTE TRIZYKLISCHE VERBINDUNGEN ALS mTOR-HEMMER |
WO2011002067A1 (ja) * | 2009-07-02 | 2011-01-06 | 武田薬品工業株式会社 | 複素環化合物およびその用途 |
EP2483263B1 (de) | 2009-09-30 | 2018-07-18 | Merck Sharp & Dohme Corp. | Heterocyclische verbindungen als erk-hemmer |
CN102638981B (zh) * | 2009-10-14 | 2015-07-22 | 默沙东公司 | 提高p53活性的取代的哌啶和其用途 |
US8541404B2 (en) | 2009-11-09 | 2013-09-24 | Elexopharm Gmbh | Inhibitors of the human aldosterone synthase CYP11B2 |
JP2013513628A (ja) | 2009-12-14 | 2013-04-22 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | スフィンゴシンキナーゼの阻害薬 |
CN101812007B (zh) * | 2010-04-27 | 2011-11-23 | 浙江大学 | 氨基吡咯类化合物及其制备方法 |
EP2608669B1 (de) | 2010-08-23 | 2016-06-22 | Merck Sharp & Dohme Corp. | Neue pyrazolo-[1,5-a-]pyrimidinderivate als mtor-hemmer |
US9133187B2 (en) | 2011-02-28 | 2015-09-15 | Array Biopharma Inc. | Serine/threonine kinase inhibitors |
JP2014514321A (ja) | 2011-04-21 | 2014-06-19 | メルク・シャープ・アンド・ドーム・コーポレーション | インスリン様増殖因子1受容体阻害剤 |
US8901142B2 (en) | 2011-07-26 | 2014-12-02 | Merck Sharp & Dohme Corp. | Fused tricyclic compounds as mTOR inhibitors |
US9187462B2 (en) | 2011-08-04 | 2015-11-17 | Array Biopharma Inc. | Substituted quinazolines as serine/threonine kinase inhibitors |
GB201113538D0 (en) | 2011-08-04 | 2011-09-21 | Karobio Ab | Novel estrogen receptor ligands |
EP2771008A4 (de) | 2011-10-28 | 2015-04-08 | Merck Sharp & Dohme | Makrozyklen zur erhöhung einer p53-aktivität und verwendungen davon |
WO2013096150A1 (en) | 2011-12-21 | 2013-06-27 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
WO2013109142A1 (en) | 2012-01-16 | 2013-07-25 | Stichting Het Nederlands Kanker Instituut | Combined pdk and mapk/erk pathway inhibition in neoplasia |
PH12015501654A1 (en) | 2012-03-01 | 2017-04-10 | Genentech Inc | Serine/threonine kinase inhibitors |
BR112015004548A2 (pt) | 2012-08-27 | 2017-08-08 | Array Biopharma Inc | inibidores de serina/treonina para tratamento de doenças hiperproliferativas |
BR112015013611A2 (pt) | 2012-12-20 | 2017-11-14 | Merck Sharp & Dohme | composto, e, composição farmacêutica |
WO2015041534A1 (en) | 2013-09-20 | 2015-03-26 | Stichting Het Nederlands Kanker Instituut | P90rsk in combination with raf/erk/mek |
US9629851B2 (en) | 2013-09-20 | 2017-04-25 | Stitching Het Nederlands Kanker Institut—Antoni Van Leeuwenhoek Ziekenhuis | ROCK in combination with MAPK pathway |
EP3363800A1 (de) | 2013-10-03 | 2018-08-22 | Kura Oncology, Inc. | Heterocyclische inhibitoren von erk und verfahren zur verwendung |
CN103922928A (zh) * | 2013-10-31 | 2014-07-16 | 北京利和知信科技有限公司 | 适用于制备烯烃聚合催化剂的环取代醚酸酯化合物 |
RU2720237C2 (ru) | 2013-11-18 | 2020-04-28 | Форма Терапеутикс, Инк. | Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет |
EP3071203B1 (de) | 2013-11-18 | 2020-12-23 | Forma Therapeutics, Inc. | Tetrahydrochinolinzusammensetzungen als bromdomänenhemmer |
WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
WO2015178770A1 (en) | 2014-05-19 | 2015-11-26 | Stichting Het Nederlands Kanker Instituut | Compositions for cancer treatment |
US10864179B2 (en) | 2015-10-01 | 2020-12-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Histone deacetylase inhibitors for the use in the treatment of drug resistant melanoma |
WO2017099591A1 (en) | 2015-12-07 | 2017-06-15 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Treatment of inhibitor resistant braf-mutant cancers |
WO2017204626A1 (en) | 2016-05-24 | 2017-11-30 | Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis | Combination therapy - combined map2k4/map3k1 and mek/erk inhibition |
WO2019144835A1 (zh) * | 2018-01-23 | 2019-08-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的哒嗪酮化合物 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB2306108A (en) | 1995-10-13 | 1997-04-30 | Merck & Co Inc | Treatment of Raf-mediated cancers with imidazole derivatives |
WO1997045412A1 (en) | 1996-05-30 | 1997-12-04 | Merck & Co., Inc. | A method of treating cancer |
GB2323845A (en) | 1997-03-31 | 1998-10-07 | Merck & Co Inc | MEK inhibiting lactones |
ES2339196T3 (es) | 1997-07-18 | 2010-05-17 | Novo Nordisk Health Care Ag | Uso de fviia o fviiai para el tratamiento de disfuncion endotelial y para la inhibicion de angiogenesis, respectivamente. |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
SK14082001A3 (sk) | 2000-02-05 | 2002-03-05 | Vertex Pharmaceuticals Incorporated | Deriváty pyrazolu ako inhibítory ERK a farmaceutická kompozícia, ktorá ich obsahuje |
WO2001056557A2 (en) | 2000-02-05 | 2001-08-09 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of erk |
BR0109188A (pt) | 2000-03-15 | 2003-03-18 | Warner Lambert Co | Diarilaminas 5-amida substituìdas como inibidores de mex |
TWI310684B (en) | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
US6897231B2 (en) | 2000-07-31 | 2005-05-24 | Signal Pharmaceuticals, Inc. | Indazole derivatives as JNK inhibitors and compositions and methods related thereto |
US20050009876A1 (en) | 2000-07-31 | 2005-01-13 | Bhagwat Shripad S. | Indazole compounds, compositions thereof and methods of treatment therewith |
US7211594B2 (en) | 2000-07-31 | 2007-05-01 | Signal Pharmaceuticals, Llc | Indazole compounds and compositions thereof as JNK inhibitors and for the treatment of diseases associated therewith |
IL154817A0 (en) | 2000-09-15 | 2003-10-31 | Vertex Pharma | Pyrazole derivatives and pharmaceutical compositions containing the same |
WO2002022610A1 (en) | 2000-09-15 | 2002-03-21 | Vertex Pharmaceuticals Incorporated | Isoxazoles and their use as inhibitors of erk |
ES2272567T3 (es) | 2000-12-21 | 2007-05-01 | Vertex Pharmaceuticals Incorporated | Compuestos de pirazol utiles como inhibidores de proteina quinasas. |
MY130778A (en) | 2001-02-09 | 2007-07-31 | Vertex Pharma | Heterocyclic inhibitiors of erk2 and uses thereof |
CA2440842A1 (en) | 2001-04-16 | 2002-10-24 | Eisai Co., Ltd. | Novel 1h-indazole compounds |
US6962936B2 (en) | 2001-04-27 | 2005-11-08 | Vertex Pharmaceuticals Incorporated | Triazole-derived kinase inhibitors and uses thereof |
CA2445357A1 (en) | 2001-04-27 | 2002-11-07 | Vertex Pharmaceuticals Incorporated | Pyrazole derived kinase inhibitors |
ATE392421T1 (de) | 2001-08-03 | 2008-05-15 | Vertex Pharma | Von pyrazol abgeleitete kinaseinhibitoren und deren verwendung |
JP4342939B2 (ja) | 2001-08-03 | 2009-10-14 | バーテックス ファーマシューティカルズ インコーポレイテッド | ピラゾール誘導キナーゼインヒビターおよびその使用 |
ES2393186T3 (es) | 2001-10-23 | 2012-12-19 | Merck Serono Sa | Derivados de azol y composiciones farmacéuticas que los contienen |
US20030187026A1 (en) | 2001-12-13 | 2003-10-02 | Qun Li | Kinase inhibitors |
AU2003237121A1 (en) * | 2002-04-26 | 2003-11-10 | Vertex Pharmaceuticals Incorporated | Pyrrole derivatives as inhibitors of erk2 and uses thereof |
AU2003233605A1 (en) | 2002-05-24 | 2003-12-12 | The University Of Utah Research Foundation | Mitogen activated protein kinase inhibitor compositions for lymphoma therapy |
AU2003241925A1 (en) | 2002-05-31 | 2003-12-19 | Eisai R&D Management Co., Ltd. | Pyrazole compound and medicinal composition containing the same |
US7205308B2 (en) | 2002-09-04 | 2007-04-17 | Schering Corporation | Trisubstituted 7-aminopyrazolopyrimidines as cyclin dependent kinase inhibitors |
US7196092B2 (en) | 2002-09-04 | 2007-03-27 | Schering Corporation | N-heteroaryl pyrazolopyrimidines as cyclin dependent kinase inhibitors |
AR041291A1 (es) | 2002-09-19 | 2005-05-11 | Schering Corp | Imidazopiridinas como inhibidores de quinasa dependientes de ciclina |
CA2522176A1 (en) | 2003-03-13 | 2004-09-30 | Vertex Pharmaceuticals Incorporated | Compositions useful as protein kinase inhibitors |
WO2005002673A1 (en) | 2003-07-03 | 2005-01-13 | Astex Therapeutics Limited | Raf kinase inhibitors |
EP1791831A4 (de) | 2003-11-19 | 2009-07-08 | Signal Pharm Llc | Verfahren zur behandlung von erkrankungen und störungen durch targeting von multiplen kinasen |
EP1715871A1 (de) | 2003-12-22 | 2006-11-02 | Gilead Sciences, Inc. | Kinase inhbitor phosphonat konjugate |
WO2005100342A1 (en) * | 2004-03-26 | 2005-10-27 | Vertex Pharmaceuticals, Incorporated | Pyridine inhibitors of erk2 and uses thereof |
WO2005100338A1 (en) | 2004-04-13 | 2005-10-27 | Astex Therapeutics Limited | 5-morpholinylmethylthiophenyl pharmaceutial compounds as p38 map kinase modulators |
DK3305776T3 (da) | 2004-05-14 | 2019-12-09 | Vertex Pharma | Pyrrol-forbindelser som inhibitorer af erk-protein-kinaser og farmaceutiske sammensætninger, der indeholder disse forbindelser |
CA2566444A1 (en) | 2004-05-14 | 2005-12-01 | Vertex Pharmaceuticals Incorporated | Prodrugs of pyrrolylpyrimidine erk protein kinase inhibitors |
WO2006040569A1 (en) | 2004-10-14 | 2006-04-20 | Astex Therapeutics Limited | Thiophene amide compounds for use in the treatment or prophylaxis of cancers |
WO2006071644A1 (en) | 2004-12-23 | 2006-07-06 | Vertex Pharmaceuticals Incorporated | Selective inhibitors of erk protein kinases and uses therof |
CN100377868C (zh) | 2005-03-24 | 2008-04-02 | 中国科学院物理研究所 | 用于磁性/非磁性/磁性多层薄膜的核心复合膜及其用途 |
WO2006136008A1 (en) | 2005-05-24 | 2006-12-28 | University Health Network | Salicylic acid hydrazones as inhibitors of the erk mapkinase pathway and for the treatment of cancer |
US8217042B2 (en) | 2005-11-11 | 2012-07-10 | Zentaris Gmbh | Pyridopyrazines and their use as modulators of kinases |
US8546404B2 (en) | 2005-12-13 | 2013-10-01 | Merck Sharp & Dohme | Compounds that are ERK inhibitors |
RU2442778C9 (ru) | 2005-12-13 | 2012-08-10 | Шеринг Корпорейшн | Новые соединения, действующие как ингибиторы erk |
US20090062355A1 (en) | 2006-04-20 | 2009-03-05 | Takeda Pharmaceutical Company Limited | Pharmaceutical Product |
US7601852B2 (en) | 2006-05-11 | 2009-10-13 | Kosan Biosciences Incorporated | Macrocyclic kinase inhibitors |
JP2009542666A (ja) | 2006-06-30 | 2009-12-03 | シェーリング コーポレイション | P53活性を増加させる置換ピペリジンおよびその使用 |
US7671832B2 (en) | 2006-07-10 | 2010-03-02 | Philips Lumileds Lighting Company, Llc | Multi-colored LED backlight with color-compensated clusters near edge |
ES2562215T3 (es) | 2007-03-28 | 2016-03-03 | Pharmacyclics Llc | Inhibidores de la tirosina quinasa de Bruton |
SG182187A1 (en) | 2007-06-08 | 2012-07-30 | Abbott Gmbh & Co Kg | 5-heteroaryl substituted indazoles as kinase inhibitors |
EP2170893A1 (de) | 2007-06-18 | 2010-04-07 | Schering Corporation | Heterocyclische verbindungen und deren verwendung als erk-inhibitoren |
NZ587504A (en) | 2008-02-21 | 2012-09-28 | Merck Sharp & Dohme | Benzopyrazole derivatives as ERK inhibitors |
-
2007
- 2007-02-13 AT AT07750497T patent/ATE485268T1/de not_active IP Right Cessation
- 2007-02-13 WO PCT/US2007/003665 patent/WO2007097937A1/en active Application Filing
- 2007-02-13 CA CA002642762A patent/CA2642762A1/en not_active Abandoned
- 2007-02-13 MX MX2008010635A patent/MX2008010635A/es unknown
- 2007-02-13 EP EP07750497A patent/EP1984331B1/de active Active
- 2007-02-13 DE DE602007009932T patent/DE602007009932D1/de active Active
- 2007-02-13 JP JP2008555293A patent/JP2009528280A/ja not_active Withdrawn
- 2007-02-13 US US11/705,709 patent/US7807672B2/en not_active Expired - Fee Related
- 2007-02-13 KR KR1020087022312A patent/KR20080103996A/ko not_active Application Discontinuation
- 2007-02-13 AU AU2007218059A patent/AU2007218059A1/en not_active Abandoned
- 2007-02-13 CN CNA2007800113120A patent/CN101415674A/zh active Pending
- 2007-02-13 ES ES07750497T patent/ES2353437T3/es active Active
- 2007-02-14 AR ARP070100620A patent/AR059493A1/es unknown
- 2007-02-15 TW TW096105603A patent/TW200745089A/zh unknown
-
2008
- 2008-08-12 IL IL193413A patent/IL193413A0/en unknown
- 2008-08-29 ZA ZA200807457A patent/ZA200807457B/xx unknown
- 2008-11-03 HK HK08112047.0A patent/HK1117159A1/xx not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
TW200745089A (en) | 2007-12-16 |
AU2007218059A1 (en) | 2007-08-30 |
IL193413A0 (en) | 2009-05-04 |
WO2007097937A1 (en) | 2007-08-30 |
CA2642762A1 (en) | 2007-08-30 |
AR059493A1 (es) | 2008-04-09 |
ZA200807457B (en) | 2009-09-30 |
ES2353437T3 (es) | 2011-03-02 |
US7807672B2 (en) | 2010-10-05 |
KR20080103996A (ko) | 2008-11-28 |
HK1117159A1 (en) | 2009-01-09 |
US20070232610A1 (en) | 2007-10-04 |
JP2009528280A (ja) | 2009-08-06 |
DE602007009932D1 (de) | 2010-12-02 |
EP1984331B1 (de) | 2010-10-20 |
MX2008010635A (es) | 2008-10-28 |
CN101415674A (zh) | 2009-04-22 |
EP1984331A1 (de) | 2008-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ATE485268T1 (de) | Pyrrolidin-derivate als erk-hemmer | |
ATE527240T1 (de) | Polyzyklische indazol-derivate als erk-hemmer | |
ATE400271T1 (de) | Aryl-pyridinderivate als 11-beta-hsd1-hemmer | |
ATE510825T1 (de) | Acylaminopyrazole als fgfr-inhibitoren | |
ATE420076T1 (de) | Indozolonderivate als 11b-hsd1-inhibitoren | |
DK2041138T3 (da) | Pyrroltriazinkinase-inhibitorer | |
DK2024375T3 (da) | Cyclopropyl-kondenserede indolobenzazepin-HCV-NS5B-hæmmere | |
CR10831A (es) | INHIBIDORES ESPIRO CETONA DE ACETIL-CoA CARBOXILASA | |
ATE467623T1 (de) | Diazepan-acetamidderivate als selektive 11-hsd1- hemmer | |
ATE452631T1 (de) | N-2-adamantanyl-2-phenoxy-acetamid-derivate als 11-betahydroxysteroid-dehydrogenase-hemmer | |
ATE452635T1 (de) | Heteroaryl-substituierte piperidin-derivate als l-cpt1-hemmer | |
ATE475649T1 (de) | Pyridincarboxamide als 11-beta-hsd1-inhibitoren | |
ATE475662T1 (de) | Dihydropyrazolopyrimidinonderivate | |
DK1989206T3 (da) | E1-aktiveringsenzymhæmmere | |
ZA200810602B (en) | Prolyl hydroxylase inhibitors | |
DE602007008837D1 (de) | Als protein-kinase-inhibitoren nutzbare dyhydrodiazepine | |
ATE483711T1 (de) | Spiroindolinonderivate | |
ATE446090T1 (de) | Thiadiazolidinone als gsk3-inhibitoren | |
ATE469905T1 (de) | Pyridopyrimidinonderivate | |
ATE512135T1 (de) | Spiroindolinonderivate | |
DK2035394T3 (da) | 2-pyrazincarboxamidderivater | |
ATE521595T1 (de) | Cyclohexylaminisochinolonderivate als rho-kinase- inhibitor | |
ATE517101T1 (de) | Als mmp-inhibitoren verwendete hydantoinderivate | |
ATE501138T1 (de) | Thiophenderivate als chk-1-inhibitoren | |
DK2074108T3 (da) | Renin-inhibitorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |